{"id":"W2897369942","doi":"10.1158/1078-0432.ccr-18-2014","title":"A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"AbbVie","keywords":"Veliparib; Carboplatin; Medicine; Etoposide; Internal medicine; Tolerability; Oncology; Pharmacokinetics; Chemotherapy; Pharmacology; Adverse effect; Surgery; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009170906,0.0007835273,0.001475228,0.000250637,0.0002790648,0.0006047884,0.0005697939,0.0004954023,0.00112209],"category_scores_gemma":[0.0006838653,0.0004042597,0.0009890986,0.0003261788,0.0005539361,0.0004480577,0.0002492603,0.002002242,0.0002597143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006583883,"about_ca_system_score_gemma":0.001089715,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004067115,"about_ca_topic_score_gemma":0.001280289,"domain_scores_codex":[0.9995102,0.0002410946,0.00003729116,0.00008718829,0.00005311588,0.00007108856],"domain_scores_gemma":[0.9994808,0.00009578784,0.0001296394,0.0000471502,0.00002998324,0.0002166801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5035309,0.1147441,0.04210801,0.001064413,0.002435933,0.0006847378,0.0006429168,0.004630504,0.1399348,0.0001850217,0.001638313,0.1884004],"study_design_scores_gemma":[0.2812029,0.6491793,0.05440854,0.00004094075,0.0007977904,0.0006870978,0.00008783359,0.002244105,0.008799114,0.0001155724,0.002405865,0.00003087357],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983606,0.0006155608,0.0002062971,0.00006468085,0.0000200893,0.0003790581,0.00007506482,0.00001282993,0.0002658681],"genre_scores_gemma":[0.9979697,0.0003699129,0.0005642374,0.0001563597,0.0000431407,0.0003163023,0.0002939513,0.000005274764,0.0002809486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001475228,"threshold_uncertainty_score":0.00485009,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1209327320517012,"score_gpt":0.5074382325365686,"score_spread":0.3865055004848674,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}